CITIC Securities research indicates that the 2026 medical insurance catalog adjustment will introduce a pre-declaration mechanism to expedite the inclusion of innovative drugs. This adjustment includes expanding the scope of eligible drugs, extending the application window for conditionally approved drugs, and establishing a coordinated pricing mechanism for competitive drugs. The policy aims to support genuine and differentiated innovation while maintaining the basic function of medical insurance. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
IMPACT Policy changes in China's medical insurance catalog could accelerate the adoption of innovative drugs, potentially impacting AI-driven drug discovery and development.
RANK_REASON The cluster discusses significant policy changes in China's medical insurance system that impact the pharmaceutical industry. [lever_c_demoted from significant: ic=1 ai=0.4]